Organovo Division Samsara Sciences Announces Multi-Year Supply Agreement With Lonza Bioscience Solutions
26. März 2018 08:05 ET
|
Organovo, Inc.
SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) today announced that its wholly-owned subsidiary, Samsara Sciences, Inc. (“Samsara”), a provider of...
Organovo to Present at H.C. Wainwright Nash Investor Conference
15. März 2018 08:05 ET
|
Organovo, Inc.
SAN DIEGO, March 15, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) today announced that Chief Executive Officer Taylor J. Crouch is scheduled to speak at the H.C....
Organovo to Present at 30th Annual ROTH Conference
08. März 2018 08:05 ET
|
Organovo, Inc.
SAN DIEGO, March 08, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) today announced that Chief Financial Officer Craig Kussman is scheduled to speak at the 30th Annual...
Organovo Announces Fiscal Third-Quarter 2018 Results; Company Updates Full-Year Fiscal 2018 Outlook
08. Februar 2018 16:05 ET
|
Organovo, Inc.
SAN DIEGO, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) today reported financial results for the fiscal third quarter of 2018 and updated its full-year fiscal...
Organovo Announces Release Date for Fiscal Third-Quarter 2018 Financial Results
18. Januar 2018 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a conference call on Thursday, February 8, 2018 at 5:00 p.m. Eastern Time (ET) to discuss...
Organovo Receives Orphan Designation From U.S. FDA for 3D Bioprinted Therapeutic Liver Tissue Treatment of Alpha-1 Antitrypsin Deficiency
26. Dezember 2017 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Dec. 26, 2017 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) today announced that the U.S. Food and Drug Administration (“FDA”) granted orphan drug designation for...
Organovo Announces Fiscal Second-Quarter 2018 Results; Company Shifts Commercial Focus to Higher-Value Disease Modeling Opportunities and Updates Full-Year Fiscal 2018 Outlook
09. November 2017 16:05 ET
|
Organovo, Inc.
SAN DIEGO, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) today reported financial results for the fiscal second quarter of 2018 and updated its full-year...
Organovo and Viscient Biosciences Collaborate to Develop Custom Research Platform for Studying Liver Disease
06. November 2017 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) and Viscient Biosciences (“Viscient”) today announced a collaboration to develop a custom research...
Organovo Presents New Preclinical Data on 3D Bioprinted Human Liver Tissues for the Treatment of Inborn Errors of Metabolism at The Liver Meeting® 2017 (AASLD)
20. Oktober 2017 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Oct. 20, 2017 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) today presented new preclinical data showing extended survival and sustained functionality of its 3D...
Organovo Announces Release Date for Fiscal Second-Quarter 2018 Financial Results
19. Oktober 2017 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a conference call on Thursday, November 9, 2017 at 5:00 p.m. Eastern Time (ET) to discuss...